Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors

by admin | Oct 7, 2020 | Press Release

Seattle, WA, October 8, 2020 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Mark Litton, PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ: ATHA), to...

Lumen Bioscience Awarded Federal Grant to Rapidly Develop Antibody-based Covid-19 Therapeutic

by admin | Sep 22, 2020 | Press Release

Seattle, WA, September 24, 2020 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, and the US Army Medical Research and Development Command (USAMRDC), operating through the Medical Technology...

Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs

by admin | Sep 1, 2020 | Press Release

Seattle, WA, September 1, 2020 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver...

Camelid Nanobodies Poised to Revolutionize Antibody Therapeutics

by admin | Aug 26, 2020 | Press Release

Lysins Unlimited: Phages’ Secret Weapon

by admin | Aug 4, 2020 | Press Release

Spirulina platform Lumen large as firm bags series A, therapies and more ahead

by admin | Aug 3, 2020 | Press Release

Read More